Market Overview

UPDATE: Cantor Fitzgerald Raises PT to $70 on Varian Medical Systems Following Meeting with Management

Share:
Related VAR
Advanced Radiotherapy Treatments Planned Using Varian's RapidPlan Commence in Australia
Studies Show that RapidArc Radiosurgery is a Viable, Time Efficient Way to Treat Multiple Brain Metastases
The Next 12 Quarters Should Say A Lot About Accuray (Seeking Alpha)

Cantor Fitzgerald reiterated its Hold rating on Varian Medical Systems (NYSE: VAR) but raised its price target from $63 to $70.

Cantor Fitzgerald said, "We hosted an investor meeting with Varian management at company headquarters as part of our Bay Area bus tour, and we note the following takeaways: 1) reimbursement is less of an overhang, but freestanding has not yet turned a corner; 2) EDGE represents a dedicated radiosurgery solution, but the early ramp should be gradual until the lung opportunity develops; and 3) margins are stable and improving. While macro concerns keep us on the sidelines (U.S. hospital capex, FX headwinds), we are raising our price target from $63 to $70 to give the company credit for its solid market leadership position."

Varian Medical Systems closed at $69.38 on Monday.

Latest Ratings for VAR

DateFirmActionFromTo
Apr 2015JP MorganDowngradesOverweightNeutral
Apr 2015JP MorganDowngradesOverweightNeutral
Jan 2015JefferiesMaintainsBuy

View More Analyst Ratings for VAR
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (VAR)

Get Benzinga's Newsletters